Search

Your search keyword '"Levin BR"' showing total 155 results

Search Constraints

Start Over You searched for: Author "Levin BR" Remove constraint Author: "Levin BR"
155 results on '"Levin BR"'

Search Results

1. Antibiotic clinical trials - The Witley Park Symposium

2. Antibiotic control of antibiotic resistance in hospitals: a simulation study

3. The ecology of nasal colonization of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus: the role of competition and interactions with host's immune response

4. Dynamics of success and failure in phage and antibiotic therapy in experimental infections

5. The evolution of heteroresistance via small colony variants in Escherichia coli following long term exposure to bacteriostatic antibiotics.

6. The dynamics of Staphylococcal infection and their treatment with antibiotics and bacteriophage in the Galleria mellonella model system.

7. Enteric Populations of Escherichia coli are Likely to be Resistant to Phages Due to O Antigen Expression.

8. Theoretical considerations and empirical predictions of the pharmaco- and population dynamics of heteroresistance.

9. The contribution of abortive infection to preventing populations of Lactococcus lactis from succumbing to infections with bacteriophage.

10. The Tradeoffs Between Persistence and Mutation Rates at Sub-Inhibitory Antibiotic Concentrations in Staphylococcus aureus .

11. Bacteriostatic cells instead of bacteriostatic antibiotics?

13. Bacterial cGAS senses a viral RNA to initiate immunity.

14. Theoretical Considerations and Empirical Predictions of the Pharmaco- and Population Dynamics of Heteroresistance.

15. What's the Matter with MICs: Bacterial Nutrition, Limiting Resources, and Antibiotic Pharmacodynamics.

16. The ecological consequences and evolution of retron-mediated suicide as a way to protect Escherichia coli from being killed by phage.

17. The book of Lambda does not tell us that naturally occurring lysogens of Escherichia coli are likely to be resistant as well as immune.

18. A methodology for using Lambda phages as a proxy for pathogen transmission in hospitals.

19. Translational demand is not a major source of plasmid-associated fitness costs.

20. Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections.

21. Proximate and ultimate causes of the bactericidal action of antibiotics.

22. It is unclear how important CRISPR-Cas systems are for protecting natural populations of bacteria against infections by mobile genetic elements.

23. Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin in Staphylococcus aureus.

24. Promises and Pitfalls of In Vivo Evolution to Improve Phage Therapy.

25. Publisher Correction: Definitions and guidelines for research on antibiotic persistence.

26. Definitions and guidelines for research on antibiotic persistence.

27. Antibiotic Killing of Diversely Generated Populations of Nonreplicating Bacteria.

28. Why put up with immunity when there is resistance: an excursion into the population and evolutionary dynamics of restriction-modification and CRISPR-Cas.

29. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification.

30. Development of macrolide resistance in Bordetella bronchiseptica is associated with the loss of virulence.

31. Leaky resistance and the conditions for the existence of lytic bacteriophage.

33. Phage-host population dynamics promotes prophage acquisition in bacteria with innate immunity.

34. Phagocytes, Antibiotics, and Self-Limiting Bacterial Infections.

35. Competitive Dominance within Biofilm Consortia Regulates the Relative Distribution of Pneumococcal Nasopharyngeal Density.

36. Evolution, human-microbe interactions, and life history plasticity.

37. Growth of bacteria in 3-d colonies.

38. A Numbers Game: Ribosome Densities, Bacterial Growth, and Antibiotic-Mediated Stasis and Death.

39. Synergy and Order Effects of Antibiotics and Phages in Killing Pseudomonas aeruginosa Biofilms.

40. Malthusian Parameters as Estimators of the Fitness of Microbes: A Cautionary Tale about the Low Side of High Throughput.

41. Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.

42. Persistence: a copacetic and parsimonious hypothesis for the existence of non-inherited resistance to antibiotics.

43. CD4 ligation on human blood monocytes triggers macrophage differentiation and enhances HIV infection.

44. Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.

45. A model-guided analysis and perspective on the evolution and epidemiology of antibiotic resistance and its future.

46. Phenotypic resistance and the dynamics of bacterial escape from phage control.

47. Normal mutation rate variants arise in a Mutator (Mut S) Escherichia coli population.

48. Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus.

49. Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids.

50. The population and evolutionary dynamics of phage and bacteria with CRISPR-mediated immunity.

Catalog

Books, media, physical & digital resources